NanoSyrinx has announced the appointment of Thomas J Farrell as its new CEO.
Farrell brings significant leadership experience in the biotherapeutics sector to his new role. He was most recently President of Oricell Therapeutics, during which time he led the launches of multiple clinical trials in the US. As well as serving as interim CEO for a variety of cell and gene therapy companies, he was the founder and CEO of both Artiva Biotherapeutics and Bellicum Pharmaceuticals.
Farrell’s drug development expertise spans oncology, immunology and monogenic diseases. Both companies founded by Farrell are National Association of Securities Dealers Automated Quotations (NASDAQ)-listed.
In his new role as CEO, Farrell succeeds NanoSyrinx founder Joe Healey. Healey will ensure a smooth transition and ongoing continuity via continued involvement in NanoSyrinx.
Farrell’s appointment will help drive NanoSyrinx’s pipeline of Nanosyringe-enabled biotherapeutics into a new phase of growth.
Edwin Moses, chairman of the board at NanoSyrinx, said: “Tom’s exceptional track record in progressing therapies from concept to clinic, combined with his global perspective, will be invaluable as NanoSyrinx moves from platform development to establishing a robust clinical pipeline.”
Farrell added: “The Nanosyringe platform has the potential to deliver a completely new class of medicines benefiting from precise biologic delivery into the cytosol of target cells. I am honoured to work with the team to move from platform development to building a clinical therapeutic pipeline and bringing transformative medicines to patients.